Hany M. Ibrahim

Hany M. Ibrahim

Auto-generated profile, based on publicly available information

Hany M. Ibrahim

Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Drug Delivery
Verified
Journal Article
Open access
MEMohammed Elmowafy
Mohammed Elmowafy
HIHany M. Ibrahim
Hany M. Ibrahim
MAMohammed A. Ahmed
Mohammed A. Ahmed
KSKhaled Shalaby
Khaled Shalaby
ASAyman Salama
Ayman Salama
HHHossam Hefesha
Hossam Hefesha
Atorvastatin (AT) is a widely used lipid-regulating drug to reduce cholesterol and triglycerides. Its poor aqueous solubility and hepatic metabolism require development of drug delivery systems able to improve its solubility and bypass hepatic effect. For this purpose, atorvastatin nanostructured lipid carriers (AT-NLCs) were prepared and characterized. AT-NLCs were prepared by emulsification using high-speed homogenization followed by ultrasonication. The prepared NLCs showed particle size between 162.5 ± 12 and 865.55 ± 28 nm while zeta potential values varied between −34 ± 0.29 and −23 ± 0.36 mV. They also showed high encapsulation efficiency (>87%) and amorphous state of the drug in lipid matrix. Pharmacokinetic parameters of optimized formulation (NLC-1; composed of 2% Gelucire® 43/01, 8% Capryol® PGMC, 2% Pluronic®F68 and 0.5% lecithin) revealed 3.6- and 2.1-fold increase in bioavailability as compared to atorvastatin suspension and commercial product (Lipitor®), respectively. Administration of NLC-1 led to significant reduction (p < .05) in the rats’ serum levels of total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL) and significant increase in high-density lipoprotein (HDL). This improvement was confirmed histologically by minimizing the associated hepatic steatosis. These investigations demonstrated the superiority of NLCs for improvement of oral bioavailability and in vivo performance of AT.

1 October 2013 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
MEMohammed Elmowafy
Mohammed Elmowafy
Tapani ViitalaTapani Viitala
Tapani Viitala
HIHany M. Ibrahim
Hany M. Ibrahim
SASherif K. Abu-Elyazid
Sherif K. Abu-Elyazid
ASAhmed Samy
Ahmed Samy
MYMarjo Yliperttula
Marjo Yliperttula

20 March 2014 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
AAAhmed Al-Abd
Ahmed Al-Abd
HIHany M. Ibrahim
Hany M. Ibrahim
ASAhmed M. Samy
Ahmed M. Samy
AKAlaa Kaseem
Alaa Kaseem
MNMohammad T. H. Nutan
Mohammad T. H. Nutan
MHMuhammad Hussain
Muhammad Hussain

1 May 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
AIAhmed H. Ibrahim
Ahmed H. Ibrahim
EREmil Rosqvist
Emil Rosqvist
JSJan-Henrik Smått
Jan-Henrik Smått
HIHany M. Ibrahim
Hany M. Ibrahim
HIHatem R. Ismael
Hatem R. Ismael
Jessica M. RosenholmJessica M. Rosenholm
Jessica M. Rosenholm

1 April 2017 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
IEIbrahim A. Elbahwy
Ibrahim A. Elbahwy
HIHany M. Ibrahim
Hany M. Ibrahim
HIHatem R. Ismael
Hatem R. Ismael
AKAlaa A. Kasem
Alaa A. Kasem

26 February 2018 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
MZMohamed F. Zidan
Mohamed F. Zidan
HIHany M. Ibrahim
Hany M. Ibrahim
MAMohsen I. Afouna
Mohsen I. Afouna
EIElsherbeny A. Ibrahim
Elsherbeny A. Ibrahim
The aim of this study was to explore the feasibility of complexing the poorly water-soluble drug atorvastatin calcium (AC) with β-cyclodextrin (β-CD) based nanosponges (NS), which offer advantages of improving dissolution rate and eventually oral bioavailability. Blank NS were fabricated at first by reacting β-CD with the cross-linker carbonyldiimidazole at different molar ratios (1:2, 1:4, and 1:8), then NS of highest solubilization extent for AC were complexed with AC. AC loaded NS (AC-NS) were characterized for various physicochemical properties. Pharmacokinetic, pharmacodynamics and histological finding of AC-NS were performed in rats. The prepared AC-NS showed particles size ranged from 408.7 ± 12.9 to 423 ± 15.9 nm while zeta potential values varied from −21.7 ± 0.90 to −22.7 ± 0.85 mV. The loading capacity varied from 17.9 ± 1.21 to 34.1 ± 1.16%. DSC, FT–IR, and PXRD studies confirmed the complexation of AC with NS and amorphous state of the drug in the complex. AC-NS displayed a biphasic release pattern with increase in the dissolution rate of AC as compared to plain AC. Oral administration of AC-NS (1:4 w/w, drug: NS) to rats led to 2.13-folds increase in the bioavailability as compared to AC suspension. Pharmacodynamics studies in rats with fatty liver revealed significant reduction (p < .05) in total cholesterol, triglyceride, LDL-C and increased level of beneficial HDL-C along with improvement in the associated liver steatosis as confirmed through photomicrographs of liver sections. In this study, we confirmed that complexation of AC with NS would be a viable approach for improving oral bioavailability and in vivo performance of AC.